HEALTHCONN BRAND OVERVIEW
Bridging Prevention, Diagnosis, and Medical Devices Precision Health and Global Healthcare Integration
Since its establishment in 2009, Healthconn Biomedical Inc. has been committed to its core philosophy of “Technology × Health,” aiming to build a comprehensive smart health ecosystem.
As a subsidiary of Foxconn Technology Group (TWSE: 2317), Healthconn Biomedical (TWSE: 6665) is a pioneer in integrating AI, big data, and genomic analysis to advance personalized health management and preventive medicine.
With over 15 years of experience in corporate health services, we provide precision health strategies and continuous monitoring for senior executives and key personnel, helping enterprises manage health risks and enhance employee wellness awareness.
Preventive Medicine × Precision Diagnostics × Smart Devices
In 2017, the group acquired Healthconn Instrument Co., Ltd. as a wholly owned subsidiary, further strengthening its presence in the medical device and diagnostic equipment supply chain. In the same year, it established Healthconn Biotech, focusing on molecular diagnostics and cancer gene testing. By introducing internationally leading platforms, the company promotes the clinical application of precision medicine.
Together, the three companies are closely connected across prevention, diagnosis, and device support, working in deep collaboration with medical institutions, research organizations, and service providers to build a data-driven, technology-centered smart health ecosystem. This ecosystem embodies the vision of “making healthcare smarter and health more accessible,” while actively aligning with the global medical industry.
HEALTHCONN
Healthconn became Taiwan’s exclusive distributor for Tempus AI’s genetic testing products, expanding its precision medicine portfolio.
Healthconn’s AI model for predicting Mycobacterium tuberculosis (MTBC) resistance to rifampicin was selected for presentation at ESCMID Global 2025, demonstrating R&D strength in infectious disease diagnostics.
Partnered with Inventec to launch the “Precision Glycemic Control & Weight Management Program” with Family Health medical devices.
Helped Far Eastern Memorial Hospital establish an automated microbiology lab.
Cancelled 604,000 treasury shares; capital adjusted to NT$453.5 million.
Coning Biotech certified as QMS-compliant medical device labeling factory.
Coning Biotech certified under GDP (Good Distribution Practice) standards.
Coning Biotech assisted Bruker MALDI Biotyper Sirius One system deployment at clinical labs.
Completed AI Smart Lab construction at National Cheng Kung University Hospital.
Genconn became distributor for Roche’s full product line and sole enterprise distributor for at-home rapid test kits.
Coning Biotech supported Shin Kong Hospital’s AI Smart Lab launch and became exclusive Taiwan distributor for Techlab diagnostic products.
Introduced Personalized Health Check Matching System.
Genconn became the exclusive Taiwan agent for Ambry Genetics.
Established Healthconn US Corp.
Genconn became the exclusive Taiwan agent for Guardant Health’s liquid biopsy products.
Coning Biotech promoted automated sample processing systems.
Capital raised to NT$452.5 million.
Capital raised to NT$452.5 million.
Founded GeneWell Life Sciences Co., Ltd.
Subsidiary Shenzhen Healthconn Technology Co., Ltd. obtains 100% equity of Zhengzhou Yongyang Testing Service Co., Ltd.
Capital increase for Genconn; launched comprehensive health membership services.
Made Healthconn Instrument Co., Ltd. a wholly owned subsidiary.
Approved for public offering of shares.
Listed on the Emerging Stock Market (Taiwan).
Capital raised to NT$336.7 million.
Established Healthconn Corp. (KY).
Established Healthconn Limited (HK).
Capital injection into overseas subsidiaries.
Founded Shenzhen Healthconn Health Technology Co., Ltd.
Capital raised to NT$287.9 million; later reduced to NT$125.7 million.
Introduced world-class high-throughput whole genome sequencers.
Launched H-Gene Project, integrating whole genome sequencing into personal health management.
Healthconn Corp. established with initial capital of NT$500,000.
Capital increase via cash injection to NT$105 million.
Further capital increase to NT$200 million.